Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling

Detailed maps of the molecular basis of the disease are powerful tools for interpreting data and building predictive models. Modularity and composability are considered necessary network features for large-scale collaborative efforts to build comprehensive molecular descriptions of disease mechanisms. An effective way to create and manage large systems is to compose multiple subsystems. Composable network components could effectively harness the contributions of many individuals and enable teams to seamlessly assemble many individual components into comprehensive maps. We examine manually-built versions of the RAS-RAF-MEK-ERK cascade from the Atlas of Cancer Signalling Network, PANTHER and Reactome databases and review them in terms of their reusability and composability for assembling new disease models. We identify design principles for managing complex systems that could make it easier for investigators to share and reuse network components. We demonstrate the main challenges including incompatible levels of detail and ambiguous representation of complexes and highlight the need to address these challenges.

[1]  Sarala M. Wimalaratne,et al.  The Systems Biology Graphical Notation , 2009, Nature Biotechnology.

[2]  Anushya Muruganujan,et al.  PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools , 2018, Nucleic Acids Res..

[3]  Peter J Hunter,et al.  Modular modelling with Physiome standards , 2016, The Journal of physiology.

[4]  Jiancheng Hu,et al.  The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy , 2020, Journal of Hematology & Oncology.

[5]  Henning Hermjakob,et al.  Reactome graph database: Efficient access to complex pathway data , 2018, PLoS Comput. Biol..

[6]  Feng He,et al.  Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms , 2018, npj Systems Biology and Applications.

[7]  Jurgen Müller,et al.  Negative feedback regulation of the ERK1/2 MAPK pathway , 2016, Cellular and Molecular Life Sciences.

[8]  Michiyuki Matsuda,et al.  Divergent Dynamics and Functions of ERK MAP Kinase Signaling in Development, Homeostasis and Cancer: Lessons from Fluorescent Bioimaging , 2019, Cancers.

[9]  Henning Hermjakob,et al.  The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..

[10]  Inna Kuperstein,et al.  Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut , 2014, Nature Communications.

[11]  Jiancheng Hu,et al.  Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy , 2020, Cells.

[12]  Inna Kuperstein,et al.  Application of Atlas of Cancer Signalling Network in preclinical studies , 2019, Briefings Bioinform..

[13]  Yosef Yarden,et al.  Feedback regulation of EGFR signalling: decision making by early and delayed loops , 2011, Nature Reviews Molecular Cell Biology.

[14]  Hiroaki Kitano,et al.  COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms , 2020, Scientific Data.

[15]  Ying Xu,et al.  ERK/MAPK signalling pathway and tumorigenesis , 2020, Experimental and therapeutic medicine.

[16]  E. Barillot,et al.  The shortest path is not the one you know: application of biological network resources in precision oncology research. , 2015, Mutagenesis.

[17]  E. Nishida,et al.  Sef is a spatial regulator for Ras/MAP kinase signaling. , 2004, Developmental cell.

[18]  Ugur Dogrusoz,et al.  Systems Biology Graphical Notation: Process Description language Level 1 Version 2.0 , 2019, J. Integr. Bioinform..

[19]  Inna Kuperstein,et al.  Comprehensive Map of the Regulated Cell Death Signaling Network: A Powerful Analytical Tool for Studying Diseases , 2020, Cancers.

[20]  E. Barillot,et al.  Atlas of Cancer Signalling Network: a systems biology resource for integrative analysis of cancer data with Google Maps , 2015, Oncogenesis.

[21]  Marek Ostaszewski,et al.  Community-driven roadmap for integrated disease maps , 2018, Briefings Bioinform..

[22]  R. Yaeger,et al.  Targeting Alterations in the RAF-MEK Pathway. , 2019, Cancer discovery.

[23]  Inna Kuperstein,et al.  Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors , 2016, Clinical Cancer Research.